NEW YORK - Beckman Coulter Life Sciences announced on Tuesday that it has inked an application development agreement with in vitro diagnostic company AmoyDx.
Under the agreement, Xiamen, China-based AmoyDx will develop "new demonstrated applications" on the Biomek NGenius Liquid Handling System, an automated liquid handler for next-generation sequencing library preparation, which Beckman unveiled last month at the Society for Laboratory Automation and Screening (SLAS) International Conference and Exhibition in Boston. The developed applications will be available to all users via an "electronic application library," according to Beckman.
Financial terms of the agreement were not disclosed.
"This is part of a robust series of development agreements, which speaks to the strength of the Biomek NGenius system coupled with the automation library preparation portfolio of partners like AmoyDx," Calvin Cortes, product manager for the Biomek NGenius system at Beckman Coulter, said in a statement.
Beckman has previously reached agreements with Illumina, IDT, and Invitae as application development partners for the Biomek NGenius, which the company said it plans to launch in the second quarter of this year.